Abbott receives Chinese approval for Xience V
The Chinese State Food and Drug Administration has approved Abbott’s Xience V everolimus-eluting coronary stent system for the treatment of coronary artery disease, the leading cause of death in China.
The Abbott Park, Ill.-based company plans a fourth quarter launch in China. With approval in China, Xience V is now available in every Asia-Pacific market, except Japan.
The clinical program for Xience V includes outstanding long-term results from the SPIRIT family of trials, including data from more than 60 patients based in China.
The Abbott Park, Ill.-based company plans a fourth quarter launch in China. With approval in China, Xience V is now available in every Asia-Pacific market, except Japan.
The clinical program for Xience V includes outstanding long-term results from the SPIRIT family of trials, including data from more than 60 patients based in China.